Pompe disease (Glycogen Storage Disease Type II, GSD II) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA)[1]. This deficiency leads to accumulation of glycogen primarily in skeletal and cardiac muscle, resulting in progressive muscle weakness, respiratory insufficiency, and in infantile-onset cases, severe cardiac involvement. The disease exists on a spectrum from classic infantile-onset Pompe disease (IOPD) with rapid progression to late-onset Pompe disease (LOPD) with slower but still progressive weakness.
Treatment of Pompe disease has been revolutionized by enzyme replacement therapy (ERT), which has dramatically improved outcomes, particularly in infantile-onset disease. However, significant challenges remain, including incomplete efficacy, immunogenicity of recombinant enzymes, and the need for multidisciplinary care. This article provides a comprehensive overview of current and emerging therapeutic approaches for Pompe disease.
Alglucosidase alfa (marketed as Myozyme in Europe and Lumizyme in the United States) was the first FDA-approved enzyme replacement therapy for Pompe disease and remains a cornerstone of treatment[2].
Characteristics:
Clinical outcomes in IOPD:
Clinical outcomes in LOPD:
Limitations:
Avalglucosidase alfa (Pombilta) is a next-generation ERT designed with improved targeting to muscle tissue[5].
Design improvements:
Clinical data:
Safety profile:
Cipaglucosidase alfa (AT-GAA) represents a novel ERT formulation designed for enhanced cellular uptake and is administered with the pharmacological chaperone miglustat[6].
Dual approach:
Clinical trials:
Advantages:
Respiratory insufficiency is a major cause of morbidity in Pompe disease and requires proactive management[7]:
Monitoring:
Interventions:
Cardiac involvement is most prominent in IOPD but can also occur in LOPD[8]:
Monitoring:
Management:
Physical therapy is essential for maintaining function in Pompe disease[9]:
Physical therapy:
Occupational therapy:
Speech therapy:
Nutritional support:
As disease progresses, assistive devices become important:
| Aid | Indication |
|---|---|
| Canes | Early ambulatory weakness |
| Walkers | Moderate weakness |
| Wheelchairs | Long-distance mobility, fatigue |
| Power wheelchair | Severe weakness |
| Home modifications | Bathroom, stairs, kitchen |
Comprehensive monitoring is essential for optimal care[10]:
Every 6-12 months:
Annually:
| Biomarker | Utility | Notes |
|---|---|---|
| Urinary glucose tetrasaccharide (Glc4) | Disease burden, treatment response | Elevates with glycogen accumulation |
| Creatine kinase (CK) | Muscle damage | Often elevated |
| GAA activity | Diagnosis, treatment monitoring | In blood, muscle |
| Anti-GAA antibodies | Treatment response, immunogenicity | Monitor in ERT-treated patients |
| Neurofilament light chain (NfL) | Neurodegeneration | Emerging biomarker |
Gene therapy represents a promising approach for long-term correction of Pompe disease[11]:
Approaches:
Clinical trials:
Challenges:
Pharmacological chaperones stabilize mutant GAA and enhance ERT delivery[12]:
Ambroxol:
Other chaperones:
Reducing glycogen substrate production may complement ERT:
Rationale for combining therapies[13]:
| Combination | Rationale |
|---|---|
| ERT + gene therapy | Different mechanisms, enhanced effect |
| ERT + chaperone | Improved enzyme stability |
| Gene therapy + chaperone | Enhanced folding |
| Multiple modalities | Maximum glycogen clearance |
IOPD requires aggressive management:
Prognosis:
LOPD has a more insidious course:
Disease course:
Pregnancy in Pompe disease requires special consideration:
The central nervous system is affected in Pompe disease, particularly in IOPD[14]:
Long-term outcomes have improved dramatically with ERT[15]:
Infantile-onset:
Late-onset:
Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management: evidence-based guidelines from the ACMG. Genet Med. 2015. ↩︎
Van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe disease. N Engl J Med. 2010. ↩︎
James E, Potter M, Pestronk A, et al. Infantile-onset Pompe disease: early diagnosis and treatment. Pediatrics. 2019. ↩︎
Schoser B, Laforet P, Horvath R, et al. Long-term outcomes of alglucosidase alfa treatment in late-onset Pompe disease. J Neurol. 2018. ↩︎
Ansong AK, Smith WL, Arya G, et al. Avalglucosidase alfa for late-onset Pompe disease: efficacy and safety. Mol Genet Metab. 2021. ↩︎
Byrne BJ, Kishnani PS, Bali D, et al. Cipaglucosidase alfa with miglustat for Pompe disease: 2-year outcomes. Mol Genet Metab. 2020. ↩︎
Stephen CD, Allen B, Smith M, et al. Respiratory outcomes in Pompe disease: a longitudinal study. Neurology. 2020. ↩︎
Lorenzoni PJ, Kay CS, Scola RH, et al. Cardiac involvement in late-onset Pompe disease. J Neurol Sci. 2020. ↩︎
Leonard JV, Whitley CB, Lyon JB. Nutritional management of Pompe disease. Ann Nutr Metab. 2016. ↩︎
Hudson J, Tarnopolsky M, Koren M, et al. Burden of disease in patients with late-onset Pompe disease. Orphanet J Rare Dis. 2017. ↩︎
Kassou N, Broomfield J, Garside J, et al. Gene therapy for Pompe disease: preclinical development. Mol Ther. 2022. ↩︎
Murray GJ, An D, Shafi R, et al. Pharmacological chaperones for Pompe disease: ambroxol and novel compounds. J Pharmacol Exp Ther. 2019. ↩︎
Kuper K, Donati CM, Dou C, et al. Combination therapy for Pompe disease: ERT and gene therapy. Gene Ther. 2021. ↩︎
Bergner CG, van der Meij R, van den Dries J, et al. Central nervous system involvement in Pompe disease. J Inherit Metab Dis. 2017. ↩︎
Pruitt M, Patel K, McGeary D, et al. Real-world outcomes in Pompe disease: a multicenter study. Neurology. 2022. ↩︎